cn-biopharma-patent-drafting
Warn
Audited by Snyk on Aug 27, 2026
Risk Level: MEDIUM
Full Analysis
MEDIUM W011: Third-party content exposure detected (indirect prompt injection risk).
- Third-party content exposure detected (medium risk: 0.30). 工作流程步骤3在进行“新颖性评估”时会把用户输入的
tech_solution提交给novelty_lite_submit/patsnap_search进行专利检索与结果获取,从而让LLM在运行时摄取由第三方来源(专利文本/摘要/描述/权利要求等)产生的内容。
Issues (1)
W011
MEDIUMThird-party content exposure detected (indirect prompt injection risk).
Audit Metadata